Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom
Article
[키워드] 95% confidence interval
acute respiratory syndrome
B.1.1.7
benefit
BNT162b2
BNT162b2 vaccine
ChAdOx1
ChAdOx1 nCoV-19
ChAdOx1 vaccines
Community
coronavirus
COVID-19
COVID-19 Infection Survey
COVID-19 vaccination
Cycle threshold value
doses
Effectiveness
Efficacy
Epidemiology
Evidence
first dose
greater
Impact
incidence
individual
Infection
infections
new SARS-CoV-2
no significant difference
nose and throat
office
Outcomes research
participant
PCR-positive
Pfizer–BioNTech
Randomly
Real-time PCR
reduce
reduced
reduction
Result
SARS-CoV-2
SARS-COV-2 infection
second dose
selected
Self-reported symptoms
single dose
Statistics
Swab
symptomatic
symptomatic infection
United Kingdom
vaccination
Vaccine
Vaccines
viral burden
viral infection
Viral load
[DOI] 10.1038/s41591-021-01410-w PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41591-021-01410-w PMC 바로가기 [Article Type] Article